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业产生广泛的影响。结论 参考 TPP 的相关经验，中国在当前药品管理法和专利法修订过程中，可通过完善信息共享
机制实现更高水平的制度互动。
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ABSTＲACT:OBJECTIVE To study the intellectual property provisions relating to drug regulation in the TPP agreement，analysize
the interaction mechanism between drug regulation and intellectual property rights on the basis of information sharing，study the possible
impact，and then discusses the references to China. METHODS This article analysizes the TPP final text and relevant research liter-
atures，study the interaction mechanism between drug regulation and intellectual property rights and the possible impact of，and then
discuss the relevantlaw of China. ＲESULTS The TPP agreement provides several intellectual property provisions relating to drug reg-
ulation，demanding the concordant relation between the registration of pharmaceutical and patent protection period，drug data protection
and patent protection，which will establish the interaction mechanism based on information sharing. The intellectual property provisions
relating to drug regulation are a summary of the experience of the TPP parties forming a coordinated and interactive mechanism between
encouraging innovation and ensuring drug safety and an attempt to a wide range practice，which will have abroad impact on the bio-
pharmaceutical industry. CONCLUSION Ｒefer to the relevant experience in TPP agreement，China can amend the Pharmaceutical
Administration Law and the Patent Law in the process of revision by improving the information sharing mechanism to achieve a higher
level of institutional interaction.
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《跨太平洋伙伴关系协定》(Trans － Pacific Part-
































































































































在 TPP第 18 章第 50 条和第 52 条规定了对药品未
公开实验数据和其他数据保护，亦采取了数据独占
权保护模式。




















































































































































































规定了 6 年的数据保护期，较 TPP 第 18 章第 50 条
的 5 年标准甚至更高。在药品专利链接制度方面，
虽然 TＲIPS并未对专利链接制度进行要求，但中国






























































TPP 第 18 章第 51 条的方案一，在药品注册申请过
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